99 related articles for article (PubMed ID: 23411970)
1. [A case of crescentic glomerulonephritis developed under oral anastrozole treatment].
Yoshimoto S; Nakatani K; Maruyama N; Fujiki K; Nakano T; Ueshima K; Fujimoto T; Oka H; Ishikawa H; Inoue F
Gan To Kagaku Ryoho; 2013 Feb; 40(2):267-70. PubMed ID: 23411970
[TBL] [Abstract][Full Text] [Related]
2. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.
Vergote I;
Eur J Cancer; 2002 Nov; 38 Suppl 6():S57-8. PubMed ID: 12409076
[No Abstract] [Full Text] [Related]
4. Successful desensitisation to Anastrozole.
Rodrigues J; Malheiro D; Botelho C; Cruz MC; Castel-Branco MG
Allergol Immunopathol (Madr); 2009; 37(1):50-1. PubMed ID: 19268063
[No Abstract] [Full Text] [Related]
5. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer.
Sendur MA; Aksoy S; Zengin N; Altundag K
J BUON; 2013; 18(4):838-44. PubMed ID: 24344006
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor.
Bremec T; Demsar J; Luzar B; Pavlović MD
Dermatol Online J; 2009 Jul; 15(7):14. PubMed ID: 19903442
[TBL] [Abstract][Full Text] [Related]
7. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
[TBL] [Abstract][Full Text] [Related]
8. Anastrozole: licence extension. No advantage over tamoxifen in advanced-stage breast cancer.
Prescrire Int; 2001 Jun; 10(53):76-7. PubMed ID: 11718168
[TBL] [Abstract][Full Text] [Related]
9. Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole.
Yagata H; Ohtsu H; Komoike Y; Saji S; Takei H; Nakamura T; Ohashi Y; Iwase T; Shimozuma K
Support Care Cancer; 2016 Feb; 24(2):683-689. PubMed ID: 26153513
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
; Buzdar A; Howell A; Cuzick J; Wale C; Distler W; Hoctin-Boes G; Houghton J; Locker GY; Nabholtz JM
Lancet Oncol; 2006 Aug; 7(8):633-43. PubMed ID: 16887480
[TBL] [Abstract][Full Text] [Related]
11. Anastrozole-induced subacute cutaneous lupus erythematosus.
Trancart M; Cavailhes A; Balme B; Skowron F
Br J Dermatol; 2008 Mar; 158(3):628-9. PubMed ID: 18070201
[No Abstract] [Full Text] [Related]
12. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
13. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
[TBL] [Abstract][Full Text] [Related]
14. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization.
Azim AA; Costantini-Ferrando M; Lostritto K; Oktay K
J Clin Endocrinol Metab; 2007 Jun; 92(6):2197-200. PubMed ID: 17356042
[TBL] [Abstract][Full Text] [Related]
15. Anastrozole can cause severe hypercalcaemia mimicking primary hyperparathyroidism.
Järhult J
Breast Cancer; 2014 May; 21(3):379-81. PubMed ID: 21290264
[TBL] [Abstract][Full Text] [Related]
16. Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy.
Valakh V; Trombetta MG; Werts ED; Labban G; Khalid MK; Kaminsky A; Parda D
Am J Clin Oncol; 2011 Jun; 34(3):245-8. PubMed ID: 20622644
[TBL] [Abstract][Full Text] [Related]
17. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
Nabholtz JM
Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer.
Kalender ME; Sevinc A; Camci C; Turk HM; Karakok M; Akgul B
Oncology; 2007; 73(5-6):415-8. PubMed ID: 18515982
[TBL] [Abstract][Full Text] [Related]
19. Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole.
Karagöz B; Ayata A; Bilgi O; Uzun G; Unal M; Kandemir EG; Ozgün A; Türken O
Onkologie; 2009 Jul; 32(7):421-3. PubMed ID: 19556821
[TBL] [Abstract][Full Text] [Related]
20. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Karnon J; Delea T; Barghout V
Eur J Health Econ; 2008 May; 9(2):171-83. PubMed ID: 17602251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
